TIL - NASDAQ

Instil Bio, Inc.

TIL·NASDAQ

$8.14

-0.37%

HealthcareBiotechnology

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$55.21M

EPS-10.7000

P/E Ratio-0.76

Earnings Date08/07/2026

til

Additional Paid-In Capital

Last Annual Value

840.94M

3-Year CAGR

5-Year CAGR

172%

10-Year CAGR

122%

Adjust for Inflation

Instil Bio, Inc. Competitors Analysis of Additional Paid-In Capital

TIL · NASDAQ

Company	Additional Paid-In Capital	CAGR 3Y	CAGR 5Y	CAGR 10Y
Instil Bio, Inc. NASDAQ:TIL	840.94M	1.4%	2.1%	N/A
Whitehawk Therapeutics Inc NASDAQ:WHWK	489.44M	9.4%	11.9%	N/A
MacroGenics, Inc. NASDAQ:MGNX	1.30B	1.2%	1.4%	8.8%
Surrozen, Inc. NASDAQ:SRZN	339.52M	9.4%	6.1%	N/A
Cognition Therapeutics, Inc. NASDAQ:CGTX	232.83M	12.0%	9.9%	N/A
Seer, Inc. NASDAQ:SEER	0.00	N/A	N/A	N/A
Spero Therapeutics, Inc. NASDAQ:SPRO	510.03M	0.8%	2.3%	N/A
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	516.80M	1.8%	7.9%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	627.98M	16.4%	19.9%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	995.22M	8.7%	8.6%	N/A
Inovio Pharmaceuticals, Inc. NASDAQ:INO	1.84B	1.9%	2.7%	12.7%

Instil Bio, Inc. Fair Value Envelope

TIL · NASDAQ

Our analysis suggests that TIL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.14, this represents a potential HIDDEN relative to our calculated worth for Instil Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $8.14

Related Guides

Blog Categories

Continue your TIL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.